Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma

The monoclonal antibody zolbetuximab (formerly IMAB362), which is being developed as a potential treatment for gastric cancer (GC), targets Claudin 18.2 (CLDN18.2), a GC biomarker. This study aimed to determine the prevalence of CLDN18.2 in primary tumors and lymph node (LN) metastases of Japanese p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Japanese journal of clinical oncology Jg. 49; H. 9; S. 870
Hauptverfasser:	Rohde, Christoph, Yamaguchi, Rin, Mukhina, Svetlana, Sahin, Ugur, Itoh, Kyogo, Türeci, Özlem
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England 01.09.2019
Schlagworte:	Adenocarcinoma - genetics Adenocarcinoma - metabolism Adenocarcinoma - pathology Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asian Continental Ancestry Group Claudins - genetics Gene Expression Regulation, Neoplastic Humans Immunohistochemistry Lymphatic Metastasis - genetics Stomach Neoplasms - genetics Stomach Neoplasms - metabolism Stomach Neoplasms - pathology prevalence immunohistochemistry gastric cancer Claudin biomarkers
ISSN:	1465-3621, 1465-3621
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!